These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29135645)

  • 1. Phosphodiesterase Type 5 Inhibitors, Sport and Doping.
    Di Luigi L; Sansone M; Sansone A; Ceci R; Duranti G; Borrione P; Crescioli C; Sgrò P; Sabatini S
    Curr Sports Med Rep; 2017; 16(6):443-447. PubMed ID: 29135645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.
    Nikolopoulos DD; Spiliopoulou C; Theocharis SE
    Fundam Clin Pharmacol; 2011 Oct; 25(5):535-63. PubMed ID: 21039821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs.
    Negro F; Di Trana A; Marinelli S
    Acta Biomed; 2022 Jan; 92(6):e2021401. PubMed ID: 35075058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the use of stimulants in out-of-competition sport samples.
    Boghosian T; Mazzoni I; Barroso O; Rabin O
    J Anal Toxicol; 2011 Nov; 35(9):613-6. PubMed ID: 22080900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and Development of the List of Prohibited Substances and Methods.
    Kinahan A; Budgett R; Mazzoni I
    Med Sport Sci; 2017; 62():39-54. PubMed ID: 28571027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
    Gur S; Kadowitz PJ; Gokce A; Sikka SC; Lokman U; Hellstrom WJ
    Curr Drug Metab; 2013 Feb; 14(2):265-9. PubMed ID: 23140258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects.
    Heuberger JAAC; Cohen AF
    Sports Med; 2019 Apr; 49(4):525-539. PubMed ID: 30411235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Between medical treatment and performance enhancement: an investigation of how elite athletes experience Therapeutic Use Exemptions.
    Overbye M; Wagner U
    Int J Drug Policy; 2013 Nov; 24(6):579-88. PubMed ID: 23582632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Athletes and Supplements: Prevalence and Perspectives.
    Garthe I; Maughan RJ
    Int J Sport Nutr Exerc Metab; 2018 Mar; 28(2):126-138. PubMed ID: 29580114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeine consumption amongst British athletes following changes to the 2004 WADA prohibited list.
    Chester N; Wojek N
    Int J Sports Med; 2008 Jun; 29(6):524-8. PubMed ID: 18027309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro.
    Aversa A; Caprio M; Antelmi A; Armani A; Brama M; Greco EA; Francomano D; Calanchini M; Spera G; Di Luigi L; Rosano GM; Lenzi A; Migliaccio S; Fabbri A
    J Sex Med; 2011 Mar; 8(3):696-704. PubMed ID: 21176111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medication, athletes and doping regulations].
    Hartgens F
    Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smokeless tobacco, sport and the heart.
    Chagué F; Guenancia C; Gudjoncik A; Moreau D; Cottin Y; Zeller M
    Arch Cardiovasc Dis; 2015 Jan; 108(1):75-83. PubMed ID: 25497687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A forensic perspective of the AFL investigation into peptides: an antidoping investigation case study.
    Harcourt PR; Marclay F; Clothier B
    Br J Sports Med; 2014 May; 48(10):810-3. PubMed ID: 24642697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
    Vernec AR
    Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Problems of the use of pseudoephedrine by athletes.
    Pokrywka A; Tszyrsznic W; Kwiatkowska DJ
    Int J Sports Med; 2009 Aug; 30(8):569-72. PubMed ID: 19382058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of prohibited substances and methods in sports: Unveiling trends, pharmacokinetics, and WADA evolution.
    Oleksak P; Nepovimova E; Valko M; Alwasel S; Alomar S; Kuca K
    Environ Toxicol Pharmacol; 2024 Jun; 108():104447. PubMed ID: 38636744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pheromones: a new ergogenic aid in sport?
    Papaloucas M; Kyriazi K; Kouloulias V
    Int J Sports Physiol Perform; 2015 Oct; 10(7):939-40. PubMed ID: 25710097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ergogenic effects of inhaled beta2-agonists in non-asthmatic athletes.
    Wolfarth B; Wuestenfeld JC; Kindermann W
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):75-87, ix. PubMed ID: 20122451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
    Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.